Pharming Group N.V.
NASDAQ:PHARBiotechnology
Healthcare
$12.48 +2.19%
+$0.28 today
- Market cap
- $882.43M
- Beta
- 0.10
- P/E (TTM)
- 77.0
- EPS (TTM)
- $0.02
52W Low $9.54High $21.34
Volume 0.01M
Average 0.01M
Income Statement
Follow revenue through to earnings.
Revenue
$377.18M
FY 2025 · Annual
+22.6% YoYOperating Income
$20.88M
FY 2025 · Annual
Net Income
$2.86M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 225.46M | 205.62M | 245.32M | 307.75M | 377.18M |
| Cost of Revenue | 23.97M | 17.56M | 25.21M | 36.66M | 45.63M |
| Gross Profit | 201.49M | 188.06M | 220.1M | 271.09M | 331.56M |
| Gross Margin | 89.4% | 91.5% | 89.7% | 88.1% | 87.9% |
| Research & Development | 79.78M | 52.53M | 68.91M | 86.1M | 98.08M |
| Selling, General & Admin | 54.56M | 68.85M | 87.5M | 102.74M | 117.44M |
| Operating Expenses | 186.12M | 169.83M | 225.49M | 280.02M | 309.75M |
| Depreciation & Amortization | 22.23M | 13.19M | 15.93M | 16.64M | 10.76M |
| EBITDA | 55.3M | 33.53M | 9.88M | 16.89M | 31.7M |
| EBITDA Margin | 24.5% | 16.3% | 4.0% | 5.5% | 8.4% |
| Operating Income | 15.37M | 18.23M | (5.39M) | (8.93M) | 20.88M |
| Operating Margin | 6.8% | 8.9% | -2.2% | -2.9% | 5.5% |
| Interest Income | 59.99K | 85K | 3.53M | 5.92M | 2.56M |
| Interest Expense | 7M | 5.36M | 5.96M | 9.05M | 21.31M |
| Other Income / Expenses | 10.79M | (3.25M) | (6.63M) | 133.58K | (8.03M) |
| Income Before Tax | 26.16M | 14.99M | (12.01M) | (8.79M) | 12.88M |
| Pre-Tax Margin | 11.6% | 7.3% | -4.9% | -2.9% | 3.4% |
| Income Tax Expense | 8.03M | 1.31M | (1.46M) | 3.47M | 10.34M |
| Net Income | 18.13M | 13.67M | (10.55M) | (12.26M) | 2.86M |
| Net Margin | 8.0% | 6.7% | -4.3% | -4.0% | 0.8% |
| EPS (Basic) | 0.23 | 0.17 | (0.14) | (0.18) | 0.04 |
| EPS (Diluted) | 0.21 | 0.16 | (0.14) | (0.18) | 0.04 |
| 87.64M | 82.54M | 65.7M | 68.92M | 71.32M | |
| 87.64M | 84.28M | 65.7M | 68.92M | 71.32M |
PHAR Earnings Waterfall · TTM
NASDAQ:PHAR · Revenue to Net Income
Key Ratios
EPS$0.18
Gross Margin87.8%
Net Margin2.6%
P/E Ratio17.4
P/S Ratio11.2
Analysis
$369.4M of revenue converted into $12.3M of net income for the selected period. Gross margin is 87.8% and net margin is 2.6%, showing how much revenue survives after costs and taxes. EPS is $0.18, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 6, 2026 | |
| 6-K | 6-K filing | Oct 27, 2026 | |
| 6-K | 6-K filing | Oct 22, 2026 | |
| 6-K | 6-K filing | Oct 14, 2026 | |
| 6-K | 6-K filing | Sep 29, 2026 |
How much revenue does PHAR generate?
Pharming Group N.V. (PHAR) reported $377.18M of revenue in fiscal 2025.
Is PHAR profitable?
Pharming Group N.V. (PHAR) reported $2.86M of net income, with a net margin of 0.8%.
Continue the stock analysis
Jump to another research area for this company.